Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Provided By GlobeNewswire
Last update: Apr 22, 2024
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to support regulatory discussions
3.89
-0.14 (-3.47%)
Find more stocks in the Stock Screener
LXEO Latest News and Analysis
3 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
